Jump to content

H2 receptor antagonist

From Wikipedia, the free encyclopedia
(Redirected from H2-receptor antagonist)

Ball-and-stick model of cimetidine, the prototypical H2 receptor antagonist

H2 antagonists, sometimes referred to as H2RAs[1] and also called H2 blockers, are a class of medications that block the action of histamine at the histamine H2 receptors of the parietal cells in the stomach. This decreases the production of stomach acid. H2 antagonists can be used in the treatment of dyspepsia, peptic ulcers and gastroesophageal reflux disease. They have been surpassed by proton pump inhibitors (PPIs). The PPI omeprazole was found to be more effective at both healing and alleviating symptoms of ulcers and reflux oesophagitis than the H2 blockers ranitidine and cimetidine.[2]

H2 antagonists, which all end in "-tidine", are a type of antihistamine. In general usage, however, the term "antihistamine" typically refers to H1 antagonists, which relieve allergic reactions. Like the H1 antagonists, some H2 antagonists function as inverse agonists rather than receptor antagonists, due to the constitutive activity of these receptors.[3]

The prototypical H2 antagonist, called cimetidine, was developed by Sir James Black[4] at Smith, Kline & French – now GlaxoSmithKline – in the mid-to-late 1960s. It was first marketed in 1976 and sold under the trade name Tagamet, which became the first blockbuster drug. The use of quantitative structure-activity relationships (QSAR) led to the development of other agents – starting with ranitidine, first sold as Zantac, which was thought to have a better adverse effect profile (later disproven), fewer drug interactions and be more potent.

Class members

[edit]
This list may not be exhaustive.

History and development

[edit]

Cimetidine was the prototypical histamine H2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.

In 1964, it was known that histamine stimulated the secretion of stomach acid, and also that traditional antihistamines had no effect on acid production. From these facts the SK&F scientists postulated the existence of two different types of histamine receptors. They designated the one acted upon by the traditional antihistamines as H1, and the one acted upon by histamine to stimulate the secretion of stomach acid as H2.

The SK&F team used a classical design process starting from the structure of histamine. Hundreds of modified compounds were synthesised in an effort to develop a model of the then-unknown H2 receptor. The first breakthrough was Nα-guanylhistamine, a partial H2receptor antagonist. From this lead, the receptor model was further refined, which eventually led to the development of burimamide, a specific competitive antagonist at the H2 receptor. Burimamide is 100 times more potent than Nα-guanylhistamine, proving its efficacy on the H2 receptor.

The potency of burimamide was still too low for oral administration. And efforts on further improvement of the structure, based on the structure modification in the stomach due to the acid dissociation constant of the compound, led to the development of metiamide. Metiamide was an effective agent; however, it was associated with unacceptable nephrotoxicity and agranulocytosis. It was proposed that the toxicity arose from the thiourea group, and similar guanidine analogues were investigated until the discovery of cimetidine, which would become the first clinically successful H2 antagonist.

Ranitidine (common brand name Zantac) was developed by Glaxo (also now GlaxoSmithKline), in an effort to match the success of Smith, Kline & French with cimetidine. Ranitidine was also the result of a rational drug design process utilising the by-then-fairly-refined model of the histamine H2 receptor and quantitative structure-activity relationships (QSAR). Glaxo refined the model further by replacing the imidazole-ring of cimetidine with a furan-ring with a nitrogen-containing substituent, and in doing so developed ranitidine, which was found to have a much better tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and ten times the activity of cimetidine.

Ranitidine was introduced in 1981 and was the world's biggest-selling prescription drug by 1988. The H2 receptor antagonists have since largely been superseded by the even more effective proton pump inhibitors (PPIs), with omeprazole becoming the biggest-selling drug for many years.

Pharmacology

[edit]

The H2 antagonists are competitive antagonists of histamine at the parietal cell's H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: Histamine released by enterochromaffin-like cells (ECL) in the stomach is blocked from binding on parietal cell H2 receptors, which stimulate acid secretion; therefore, other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

Clinical uses

[edit]

H2 antagonists are used by clinicians in the treatment of acid-related gastrointestinal conditions, including:[7]

People who suffer from infrequent heartburn may take either antacids or H2 receptor antagonists for treatment. The H2 antagonists offer several advantages over antacids, including longer duration of action (6–10 hours vs 1–2 hours for antacids), greater efficacy, and ability to be used prophylactically before meals to reduce the chance of heartburn occurring. Proton pump inhibitors, however, are the preferred treatment for erosive esophagitis since they have been shown to promote healing better than H2antagonists.[citation needed]

Adverse effects

[edit]

H2 antagonists are generally well tolerated, with the exception of cimetidine, which more commonly elicits the following adverse drug reactions (ADRs) than other H2 antagonists:

Infrequent ADRs include hypotension. Rare ADRs include headache, tiredness, dizziness, confusion, diarrhea, constipation, and rash.[7] In addition, gynecomastia occurred in 0.1% to 0.5% of men treated for non-hypersecretory conditions with cimetidine for 1 month or longer and in about 2% of men treated for pathologic hypersecretory conditions; in even fewer men, cimetidine may also cause loss of libido, and impotence, all of which are reversible upon discontinuation.[9]

A 31-study review found that the overall risk of pneumonia is about 1 in 4 higher among H2 antagonist users.[10]

According to a 2022 umbrella review of meta-analyses, the use of H2 receptor antagonist is associated with pneumonia, peritonitis, necrotizing enterocolitis, Clostridioides difficile infection, liver cancer, gastric cancer, and hip fracture diseases.[11]

Research

[edit]

Bladder diseases

[edit]

Histamine can cause bladder inflammation and contribute to the symptoms of such bladder diseases as cystitis (inflammation of the bladder) or painful bladder disease. Histamine binds to H2 receptors in the bladder smooth muscle, leading to relaxation[contradictory] of the bladder muscle and promotion of urine storage. Histamine does not seem to have a direct role in the development of bladder diseases, but it can contribute to bladder inflammation and associated symptoms.

H2 receptors in the bladder play a role in regulating bladder contraction.

H2 receptor antagonists have been shown to reduce bladder contractions and improve bladder function in animal studies.[12][13][14] Blocking the activation of H2 receptors in the bladder leads to decreased bladder contractions and improved urine storage. While H2 receptor antagonists may have a potential role in managing bladder conditions such as overactive bladder, they are not typically used in treating cystitis or painful bladder disease, and their mechanism of action in bladder diseases is still not fully understood. There is limited research that histamine H2 receptor antagonists can potentially alleviate symptoms of cystitis[15][16] or painful bladder disease.[17][18][19]

Drug interactions

[edit]
Skeletal formula of famotidine. Unlike cimetidine, famotidine has no significant interactions with other drugs.

With regard to pharmacokinetics, cimetidine in particular interferes with some of the body's mechanisms of drug metabolism and elimination through the liver cytochrome P450 (CYP) pathway. To be specific, cimetidine is an inhibitor of the P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4. By reducing the metabolism of drugs through these enzymes, cimetidine may increase their serum concentrations to toxic levels. Many drugs are affected, including warfarin, theophylline, phenytoin, lidocaine, quinidine, propranolol, labetalol, metoprolol, methadone, tricyclic antidepressants, some benzodiazepines, dihydropyridine calcium channel blockers, sulfonylureas, metronidazole,[20] and some recreational drugs such as ethanol and methylenedioxymethamphetamine (MDMA).

The more recently developed H2receptor antagonists are less likely to alter CYP metabolism. Ranitidine is not as potent a CYP inhibitor as cimetidine, although it still shares several of the latter's interactions (such as with warfarin, theophylline, phenytoin, metoprolol, and midazolam).[21] Famotidine has negligible effect on the CYP system, and appears to have no significant interactions.[20]

See also

[edit]

References

[edit]
  1. ^ Francis KL Chan (21 April 2017). "ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA". ClinicalTrials.gov. Archived from the original on 1 December 2018. Retrieved 1 November 2017.
  2. ^ Eriksson S, Långström G, Rikner L, Carlsson R, Naesdal J (1995). "Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis". Eur J Gastroenterol Hepatol. 7 (5): 467–75. PMID 7614110.. A correction was published in European Journal of Gastroenterology & Hepatology 1996;8:192.
  3. ^ Panula P, Chazot PL, Cowart M, et al. (2015). "International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors". Pharmacological Reviews. 67 (3): 601–55. doi:10.1124/pr.114.010249. PMC 4485016. PMID 26084539.
  4. ^ "Sir James W. Black - Biographical". Nobelprize.org. Archived from the original on 23 April 2015. Retrieved 7 April 2015.
  5. ^ Guengerich FP (2011). "Mechanisms of drug toxicity and relevance to pharmaceutical development". Drug Metabolism and Pharmacokinetics. 26 (1): 3–14. doi:10.2133/dmpk.dmpk-10-rv-062. PMC 4707670. PMID 20978361.
  6. ^ Gasbarrini G, Gentiloni N, Febbraro S, Gasbarrini A, Di Campli C, Cesana M, Miglio F, Miglioli M, Ghinelli F, d'Ambrosi A, Amoroso P, Pacini F, Salvadori G (1997). "Acute liver injury related to the use of niperotidine". Journal of Hepatology. 27 (3): 583–586. doi:10.1016/s0168-8278(97)80365-0. PMID 9314138.
  7. ^ a b Rossi S (Ed.) (2005). Australian Medicines Handbook 2005. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-9-3.[page needed]
  8. ^ Miller RD, Eriksson L, Fleisher LA, Wiener-Kronish JP (25 November 2014). Miller's Anesthesia Airway management in the Adult (8th ed.). Elsevier. pp. 1647–1681.
  9. ^ Drugs.com "Cimetidine Side Effects" Archived 2017-11-07 at the Wayback Machine
  10. ^ Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS (2011). "Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis". CMAJ. 183 (3): 310–9. doi:10.1503/cmaj.092129. PMC 3042441. PMID 21173070. (adjusted odds ratio [OR] 1.22)
  11. ^ Meng R, Chen LR, Zhang ML, Cai WK, Yin SJ, Fan YX, Zhou T, Huang YH, He GH (2023). "Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta-Analyses". The Journal of Clinical Pharmacology. 63 (1): 7–20. doi:10.1002/jcph.2147. PMID 36039014. S2CID 251931004.
  12. ^ Aizawa N, Fujita T (2023). "Physiological Role of Histamine H2 Receptor on Bladder Sensory Function in Rats". Continence. 7: 100808. doi:10.1016/j.cont.2023.100808.
  13. ^ Stromberga Z, Chess-Williams R, Moro C (2019). "Histamine modulation of urinary bladder urothelium, lamina propria and detrusor contractile activity via H1 and H2 receptors". Scientific Reports. 9 (1): 3899. Bibcode:2019NatSR...9.3899S. doi:10.1038/s41598-019-40384-1. PMC 6405771. PMID 30846750.
  14. ^ Rudick CN, Schaeffer AJ, Klumpp DJ (2009). "Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis". BMC Urology. 9: 16. doi:10.1186/1471-2490-9-16. PMC 2781023. PMID 19909543.
  15. ^ Zhou H, Zhou Y, Ping Y, Tian S, Li G, Cui Y, Zheng B (2019). "The combination of loratadine with famotidine to relieve the symptoms of urinary frequency in female patients with bladder function disorders：First report of three cases". Journal of Clinical Pharmacy and Therapeutics. 44 (5): 796–799. doi:10.1111/jcpt.12845. PMID 31049996. S2CID 143433911.
  16. ^ Thilagarajah R, Witherow RO, Walker MM (2001). "Oral cimetidine gives effective symptom relief in painful bladder disease: A prospective, randomized, double-blind placebo-controlled trial". BJU International. 87 (3): 207–212. doi:10.1046/j.1464-410x.2001.02031.x. PMID 11167643. S2CID 41415547.
  17. ^ Thilagarajah R, Witherow RO, Walker MM (2001). "Oral cimetidine gives effective symptom relief in painful bladder disease: A prospective, randomized, double-blind placebo-controlled trial". BJU International. 87 (3): 207–212. doi:10.1046/j.1464-410x.2001.02031.x. PMID 11167643. S2CID 41415547.
  18. ^ Dasgupta P, Sharma SD, Womack C, Blackford HN, Dennis P (2001). "Cimetidine in painful bladder syndrome: A histopathological study". BJU International. 88 (3): 183–186. doi:10.1046/j.1464-410x.2001.02258.x. PMID 11488726. S2CID 19989194.
  19. ^ Shan H, Zhang EW, Zhang P, Zhang XD, Zhang N, Du P, Yang Y (2019). "Differential expression of histamine receptors in the bladder wall tissues of patients with bladder pain syndrome/Interstitial cystitis - significance in the responsiveness to antihistamine treatment and disease symptoms". BMC Urology. 19 (1): 115. doi:10.1186/s12894-019-0548-3. PMC 6852726. PMID 31718622.
  20. ^ a b Humphries TJ, Merritt GJ (August 1999). "Review article: drug interactions with agents used to treat acid-related diseases". Alimentary Pharmacology & Therapeutics. 13 (Suppl 3): 18–26. doi:10.1046/j.1365-2036.1999.00021.x. PMID 10491725. S2CID 2089156.
  21. ^ Kirch W, Hoensch H, Janisch HD (1984). "Interactions and non-interactions with ranitidine". Clinical Pharmacokinetics. 9 (6): 493–510. doi:10.2165/00003088-198409060-00002. PMID 6096071. S2CID 10715649.
Retrieved from "https://en.wikipedia.org/w/index.php?title=H2_receptor_antagonist&oldid=1252295761"